FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to pharmaceutical composition for intranasal administration contains zolmitriptan that is agonist of 5-HT1-receptor and pharmaceutically acceptable carrier. The composition has pH value less 6.0. The composition can be used for treatment of migraine and related disorders. The composition shows the improved stability in storage and provides effective relief for patients suffering with migraine.
EFFECT: improved and valuable medicinal properties of composition.
11 cl, 1 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2010 |
|
RU2710372C2 |
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2019 |
|
RU2762725C2 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2767436C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING 5HT1-RECEPTOR AGONIST | 2002 |
|
RU2285526C2 |
| SUBLINGUAL SPRAY COMPOSITION CONTAINING DIHYDROARTEMISININ | 2010 |
|
RU2501550C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING OR RELIEVING MOVEMENT DISORDERS AND ITS APPLICATION | 2011 |
|
RU2611376C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
| TREATMENT OF GASTROPARESIS ASSOCIATED SYMPTOMS FOR WOMEN | 2012 |
|
RU2616520C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| 3-[2-(DIMETHYLAMINO)-ETHYL]-N-METHYL-1H-INDOLE-5-METHANE SULFONEAMIDE SULFATE SALT (2:1) OR ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF, METHOD OF HEADACHE TREATMENT | 1991 |
|
RU2108328C1 |
